Systemic therapy, involving TKIs of the VEGF pathway and mTOR inhibitors, has been shown to improve CSS in metastatic ccRCC and in the rare studies available on VHL only cohorts (71–81). Here, MTOR is linked to nonpapillary renal cell carcinoma.